3M™ Integrated Dose by Dose Counter and the 3M™ Nasal Metered Dose Inhaler (MDI) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

3M Drug Delivery: Partner with the Expert

3M™ Integrated Dose by Dose Counter and the 3M™ Nasal Metered Dose Inhaler (MDI)

As inventors of the very first metered dose inhaler (MDI), and being behind the latest MDIs, 3M has been at the forefront of inhalation technology for over 50 years. Our experience spans the entire system, from feasibility to selecting the right components – through to commercial scale production.

3M supports pharmaceutical customers globally providing a competitive edge with patient-centered innovations and devices that set our customers apart. Whether you’re looking for a primary contract fill manufacturer, a second source of supply, for cold or pressure fill, our trusted cGMP manufacturing capabilities provide you with reassurance that your product will be available for market.

We take the risk out of commercializing your new product, from start to finish.

Watch our video and learn more

Company name:  3M Drug Delivery Systems

Website: Watch our video and learn more

E-mail: DDS@mmm.com
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
FindPharma Custom Search

Click here